Tony Hagen
OncLive.com
Plainsboro Township, NJ, United States
Contact Tony
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Tony:
SM-88 Shows Efficacy in Pancreatic, Prostate Cancers
Having a late-stage treatment for pancreatic cancer that avoids many of the adverse events associated with chemotherapy would be a boon for patients. → Read More
FDA Streamlines Expanded Access for Oncology Agents
The FDA has unveiled what it describes as a pilot “concierge service” for oncologists and patients seeking information and assistance with expanded access to investigational therapies. → Read More
Open Source System Debuts for EHR Data Sharing
A consortium of cancer care institutions released details on a prototype system designed to link electronic health record systems to provide a source of real-world patient information to guide research and improve cancer treatment. → Read More
Large Myeloma Study Aims to Analyze Multiple Regimens
Therapy for patients with multiple myeloma encompasses many agents and potential combinations, but truly personalizing care will require knowing how those agents interact for maximum efficacy and incorporating patient preferences for toxicity into the care plan. → Read More
Genetic Testing Recommended for All Patients With Pancreatic Cancer
In a provisional clinical opinion, an expert panel convened by the American Society of Clinical Oncology has recommended that patients with pancreatic cancer undergo assessment of risk for hereditary syndromes that contribute to higher likelihood of pancreatic cancer. → Read More
The Debate Over Early Screening for Pancreatic Cancer Continues
Higher costs associated with advanced stage pancreatic cancer, are potentially avoidable with screening and earlier treatment. However, the US Preventive Services Task Force in an ongoing draft review has reaffirmed its stance against screening in asymptomatic individuals. → Read More
NCCN Guidelines Gain Traction Around the Globe
Global use of cancer management guidelines from the National Comprehensive Cancer Network has climbed rapidly in recent years. → Read More
Treatment Options Improve for Older Patients with AML
More options are available than ever before for treating older patients with acute myeloid leukemia and fresh hopes are resting on combinations of venetoclax plus hypomethylating agents. → Read More
Newer Agents Extend Survival and Reduce Toxicity in CLL
New agents in chronic lymphocytic leukemia are significantly strengthening the armamentarium, particularly next-generation BTK and PI3K inhibitors, and although toxicities remain an issue, tolerability may be improving. → Read More
Chemotherapy Poised to Have Minor Role in Future CLL Treatment
The day is approaching that chemotherapy may be unnecessary for the treatment of patients with chronic lymphocytic leukemia. → Read More
BCMA-Directed CAR T-Cell Therapy Makes Strong Entrance in Myeloma
B-cell maturation antigen-specific chimeric antigen receptor T-cell therapy is delivering impressive results in multiple myeloma, demonstrating durable responses and acceptable toxicities. → Read More
Making the Case for Earlier CAR T-Cell Therapy in Lymphoma
Real-world data on the use of chimeric antigen receptor T-cell therapy in large B-cell lymphoma bear out the pivotal results from ZUMA-1 and demonstrate not only that the treatment approach is here, but also that it’s time to address issues of efficacy, safety, cost, and moving this approach into earlier lines of therapy. → Read More
Immuno-Oncology Expert Highlights How Steroid Dosage Influences Response
Different patterns of response are associated with the dosages of immunosuppressants used to manage the adverse effects of immunotherapies. → Read More
Novel Agents, Earlier Diagnosis Driving Survival Gains in CLL
The median overall survival for patients with chronic lymphocytic leukemia has more than tripled since the 1970s, primarily due to an ever-expanding armamentarium of novel agents and earlier diagnosis. → Read More
Ansell Discusses Combination Potential in Hodgkin Lymphoma
Steven M. Ansell, MD, PhD, discusses the efficacy of PD-L1 blockade in Hodgkin lymphoma, patient treatment that has encouraged him to look for deeper solutions, alternative drug combinations that appear to be making headway, and potential avenues of discovery for the future. → Read More
Treatment Options for CD30-Positive PTCL Subtypes
Steven M. Horwitz, MD, discusses the best strategy for the treatment of CD30-positive peripheral T-cell lymphomas. → Read More
Bleomycin Linked to High Rate of Pulmonary Disorders among Patients with Hodgkin Lymphoma
A retrospective study of patients with Hodgkin lymphoma found high rates of sequelae including pulmonary events and cardiovascular disease following frontline treatment with chemotherapy including bleomycin. → Read More
Navigating the Toxicities of Novel-Novel Combinations in Lymphoma
Combinations of novel drugs in lymphomas have the potential to overcome resistance to therapy but come with sometimes unexpected adverse events that demand careful monitoring. → Read More
West Coast Study Rates Cancer Centers by Cost and Quality
In a groundbreaking study of costs and quality of cancer care among cancer clinics in the state of Washington, investigators found wide disparity in end-of-life care, suggesting that improvements in cost and quality could be attained if treatment centers share information on what works and endeavor to improve. → Read More
Colorectal Cancer Treatment Twice as Costly in US Than Canada, Despite Similar Outcomes
A study that compared costs of treatment for metastatic colorectal cancer in Western Washington and the province of British Columbia in Canada found that prices were more than twice as high for the US patients than for their Canadian counterparts, with no significant difference in outcomes. → Read More